Beta blockers are not interchangeable: what actually differs
Beta blockers share a medicine-class name, but they differ in receptor selectivity, additional actions, duration, formulation and evidence for particular conditions. Singapore ACE guidance splits them into cardioselective agents (atenolol, bisoprolol, metoprolol, nebivolol) and non-selective agents (propranolol, carvedilol). The same number of milligrams of two different beta blockers is not an equivalent dose. The clinically useful comparison begins with why it was prescribed, the exact release form, pulse and blood pressure, other conditions and interacting medicines.
Key takeaways
- “Cardioselective” means greater preference for beta-1 receptors at usual exposure, not a guarantee that the lungs or other beta-2 tissues are unaffected: the Zebeta label notes that bisoprolol’s selectivity is not absolute and lessens at higher doses.
- Evidence is indication- and formulation-specific: the ACE table lists bisoprolol, metoprolol and nebivolol for chronic heart failure and reserves propranolol for migraine prevention or essential tremor, so a beta blocker chosen for one role is not automatically a substitute for the other.
- Slow pulse, dizziness, worsening breathlessness, asthma/COPD, diabetes and abrupt interruption all require product-specific clinical advice rather than class-wide assumptions.
What does receptor selectivity change?
Beta-1 receptors are prominent in the heart, while beta-2 receptors contribute to airway and vascular responses. Beta-1-selective medicines such as bisoprolol, metoprolol and atenolol preferentially block beta-1 receptors at typical exposure. Propranolol blocks both beta-1 and beta-2 receptors.
The Zebeta prescribing information states that bisoprolol’s cardioselectivity is not absolute: at higher doses it also inhibits beta-2 receptors in the bronchial and vascular muscle, so the label advises the lowest effective dose to retain selectivity. A history of asthma, wheeze or COPD therefore still belongs in the medicine review, and nonselective blockade raises more concern about bronchospasm than a cardioselective one; a class label alone cannot settle an individual risk-benefit decision on its own.
Carvedilol and labetalol block alpha receptors as well as beta receptors, which changes their vascular effects and clinical uses. The ACE table places carvedilol among the non-selective agents used for portal hypertension in cirrhosis. An online “equivalent dose” chart does not capture that kind of difference.
Why does the reason for treatment matter more than the class name?
Beta blockers may be used for selected rhythm disorders, angina, heart failure, blood pressure, migraine prevention, tremor, thyroid-symptom control or other indications. The ACE table assigns the cardioselective agents to coronary heart disease, chronic heart failure, acute coronary syndrome and some arrhythmias, and the non-selective agents to migraine prevention, essential tremor or portal hypertension in cirrhosis, so evidence for one indication does not transfer across the class.
| Example | Distinguishing question | Unsafe inference |
|---|---|---|
| Atenolol | Is a beta-1-selective agent being used for a cardiovascular reason? | That the milligram number converts directly to another beta blocker |
| Bisoprolol | Is it part of an evidence-based heart-failure or rate-control plan? | That cardioselectivity removes all respiratory concern |
| Metoprolol | Which salt and immediate- or extended-release formulation is prescribed? | That all metoprolol formulations have identical evidence and schedules |
| Propranolol | Is nonselective blockade being used for a cardiac or non-cardiac indication? | That it can replace a beta-1-selective medicine without changing risks |
The ACE table’s cardioselective column names bisoprolol, metoprolol and nebivolol for chronic heart failure; its non-selective column separately credits carvedilol with heart-failure evidence. The American Heart Association’s heart-failure pages name specific beta blockers too, not the whole class. Among metoprolol products, only the succinate extended-release form carries that heart-failure evidence; other metoprolol presentations do not inherit it.
For uncomplicated hypertension, Singapore ACE guidance advises against initiating beta blockers as routine first-line monotherapy for blood pressure control, unless the patient also needs heart-rate reduction or has a cardiac comorbidity such as stable ischaemic heart disease, chronic heart failure or atrial fibrillation. The same guidance found that, in patients aged 60 or older, ACE inhibitors, ARBs, calcium channel blockers and thiazide or thiazide-like diuretics were associated with better outcomes against stroke and all-cause mortality than beta blockers. Neither finding erases their value in angina, selected arrhythmias or specific heart-failure care; it shows why the indication must be visible.
Why can pulse and exercise feel different?
Beta blockade reduces the heart-rate response to sympathetic stimulation. A person may see a lower resting pulse and a smaller heart-rate rise during exercise. Fatigue, cold hands or feet, dizziness and reduced exercise tolerance can occur, but symptoms can also come from the underlying condition, anaemia, infection or another medicine.
An exercise watch target calculated from age may therefore be misleading for someone taking a beta blocker. Exercise intensity and rehabilitation targets should be based on the clinical plan and symptoms, not on achieving a consumer-device heart-rate zone.
A very slow pulse with fainting, chest discomfort, severe dizziness or confusion needs urgent assessment. Do not respond by skipping, doubling or alternating doses without advice.
What do asthma and diabetes change?
Nonselective beta blockers can block beta-2 receptors in the airways, while beta-1 selectivity is incomplete. The InnoPran XL label lists bronchial asthma among its contraindications outright. The Zebeta label is more permissive: it states that patients with bronchospastic disease should in general not receive beta blockers, but that bisoprolol may be used with caution in those who do not respond to, or cannot tolerate, other antihypertensive treatment, provided a bronchodilator is kept available. Anyone with asthma, recurrent wheeze or COPD needs the exact drug and indication reviewed. New or worsening wheeze, chest tightness or breathlessness should not be dismissed as an expected inconvenience.
Beta blockers can also blunt some adrenergic warning signs of low blood glucose, particularly a rapid heartbeat. The Zebeta label notes that nonselective beta blockers may potentiate insulin-induced hypoglycaemia and delay recovery of blood glucose, and that this is less likely, though not eliminated, with a cardioselective agent. The InnoPran XL label confirms that dizziness and sweating may still occur even when the fast heartbeat is masked. People using insulin or medicines that can cause hypoglycaemia need an individual monitoring plan rather than relying on palpitations as the warning.
Why is abrupt stopping a separate safety issue?
Long-term beta blockade changes how the cardiovascular system responds to sympathetic stimulation. The InnoPran XL label reports that exacerbations of angina pectoris and myocardial infarction have followed abrupt discontinuation, and advises a gradual reduction in patients with ischaemic heart disease rather than a sudden stop. The Zebeta label separately warns that abrupt cessation in patients with coronary artery disease has been followed by worsening angina, myocardial infarction or ventricular arrhythmia, and advises tapering therapy under observation. Neither warning is an instruction to continue despite an emergency reaction; it means routine stopping or switching requires a clinician-led plan.
The same principle applies before surgery or a procedure. The prescriber, anaesthetist and procedural team need to know the exact medicine and formulation. Do not omit it simply because fasting instructions mention tablets in general.
What changes the answer?
- The indication. Heart failure, angina, arrhythmia, hypertension, migraine and tremor do not share one evidence base.
- The formulation. Immediate- and extended-release products can differ in schedule and clinical-trial evidence.
- Asthma or COPD. Selectivity and current respiratory control affect the discussion, but “cardioselective” is not absolute protection.
- Pulse, conduction and blood pressure. Bradycardia, heart block, postural symptoms and interacting rate-lowering medicines can alter suitability.
- Diabetes or fasting. Hypoglycaemia warning signs and illness/poor intake need a specific plan.
- Kidney or liver function, age and pregnancy. These can change exposure, monitoring and medicine choice.
Which symptoms need prompt assessment?
Call emergency services for severe breathlessness, collapse, new chest pain, fainting with a very slow or irregular pulse, blue or grey colour, or signs of a severe allergic reaction. Seek prompt medical advice for new wheeze, repeated near-fainting, a markedly slower pulse with symptoms, worsening swelling or breathlessness, or a major decline in exercise tolerance.
At a medicine review, bring the exact packets and record the indication, formulation, pulse and blood-pressure pattern, respiratory history, diabetes medicines and all other rate-lowering drugs. The blood-pressure class guide provides the wider hypertension context; the heart-failure condition page explains why bisoprolol, metoprolol and nebivolol carry a disease-specific role that other beta blockers do not share.
Sources
- Singapore Agency for Care Effectiveness: Hypertension: tailoring the management plan to optimise blood-pressure control.
- US FDA: Zebeta (bisoprolol fumarate) prescribing information.
- US FDA: InnoPran XL (propranolol hydrochloride extended release) prescribing information.
- American Heart Association: Medications used to treat heart failure.
